Barry Resnik, MD, FAAD

Discover how HS clinicians track real-life progress, set 3–4 month treatment goals, and build trust with patient-centered questions and empathy.

New HS therapies emerge as JAK inhibitors show trial promise, safer long‑term data, and combo strategies expand options for severe and teen patients.

Why hidradenitis suppurativa patients go undertreated—fatigue, clinician risk fears, and insurance hurdles—plus tips to access modern biologics.

Dermatologists spot hidradenitis suppurativa early, explain it’s inflammatory, and start medical-surgical care and biologics to prevent lasting damage.

Learn how clinicians spot hidradenitis suppurativa early—recurring abscesses, bridging comedones, atypical sites, and when MRI helps distinguish Crohn’s.

Learn why hidradenitis suppurativa is often mistaken for infection and who it affects—key myths that delay diagnosis and proper care.

Learn why hidradenitis suppurativa isn’t an infection, isn’t caused by poor hygiene, and can affect anyone—key myths delaying diagnosis.

This episode examines the persistent barriers that contribute to the delayed diagnosis of hidradenitis suppurativa, highlighting the need for greater disease awareness, proactive screening by frontline providers, and the growing role of patient self-advocacy in improving earlier detection.

This episode explores the multidimensional burden of hidradenitis suppurativa, highlighting its physical, emotional, and economic impacts on patients while emphasizing the importance of compassionate care and improved disease recognition.